Non-Invasive Prenatal Testing Market To Reach A Valuation Of USD 2.5 Billion By 2028

January 12, 2022

According to the research report titled ‘Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028’, available with MarketStudyReport, the U.S. non-invasive prenatal testing market is anticipated to reach a valuation of USD 2.5 billion by 2028.

As per the report findings, the primary factors driving the growth of the U.S. non- invasive prenatal testing market are an increase in the per capita income, rise in the occurrences of chromosomal aneuploidies in fetuses, improved awareness about non-invasive testing methods, and focus on the reimbursement of NIPT.

Request sample copy of this report:

For the uninitiated, pre-natal tests are done during the course of pregnancy to ensure that the health of the baby as well as the mother is not compromised.

Notably, as a result of ACOG guidelines that recommend prenatal testing for all pregnancies, and the rising inclination of expectant mothers towards non-invasive prenatal testing techniques rather than invasive ones have made a positive impact on the industry growth.

Apart from the growth drivers and opportunities, the research literature provides critical information regarding the market augmentation history and current business landscape in order to make estimations about growth rate and valuation over 2021-2028. Also, insights into regulatory frameworks, recent competitive developments, distribution channels, mergers & acquisitions, collaboration & partnership deals, and licensing agreements, that can help in understanding the potential of the overall non-invasive prenatal testing market in the US.

Additionally, the report sheds light on the average number of NIPT tests performed during 2015-2020, detailing average as well as high risk prenatal tests that took place over years, along with the predictions for the period 2021-2028.

From a competitive frame of reference, key players influencing the U.S. non-invasive prenatal testing industry dynamics are Natera Inc., Myriad Genetics, Integrated Genetics (LabCorp), GenPath, Centogene, Quest Diagnostics, Illumina Inc., Progenity Inc., Invitae Corporation, PerkinElmer, Agilent Technologies Inc., Yourgene Health, and Ariosa Diagnostics Inc. (Roche). These players are focusing on R&D for innovative methods to meet the evolving consumer demands, thereby gaining a competitive edge in the marketplace.

Chat with us